The European Medicine Agency’s Commitee for Medicinal Products for Human Use has issued a positive opinion on Pfizer’s (NYSE:PFE) antibody-drug conjugate Tivdak (tisotumab vedotin) for metastatic cervical cancer.
Pfizer has said that the treatment works “due to the binding of the
